Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AmpliMed Corporation
ClinicalTrials.gov Identifier:
NCT00327288
First received: May 17, 2006
Last updated: June 22, 2015
Last verified: June 2015